MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics shares have declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MapLight Therapeutics has released topline results from the ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. Despite some positive data, the overall readout is described as mixed, leading to a drop in the company's share price.
Coverage from BioPharma Dive and Fierce Biotech emphasizes the decline in stock value despite the positive aspects of the data. Finimize notes that biotech and AI stocks were generally hit by mixed news, while Investing.com reports that TD Cowen has maintained a Buy rating for MapLight stock following the data release.
Future attention will likely center on the detailed analysis of the ZEPHYR trial results as reported by Psychiatric Times and the subsequent market reaction to the maintained analyst rating.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 24m ago.
Quick answers
What drug was tested in the ZEPHYR trial?
The trial tested ML-007C-MA for the treatment of schizophrenia.
How did the market react to the trial results?
MapLight shares sank following the mixed Phase 2 readout.
What is the current analyst sentiment from TD Cowen?
TD Cowen has held a Buy rating for MapLight Therapeutics stock after the trial data.
Coverage (7)
- Maplight aims to differentiate muscarinic agonist from competitors BioWorld News · 10h ago
- MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose Yahoo Finance · 10h ago
- MapLight dives despite positive data for schizophrenia drug BioPharma Dive · 10h ago
- MapLight Therapeutics stock holds Buy rating at TD Cowen after trial data Investing.com · 10h ago
- Biotech And AI Stocks Got Hit On Mixed News Finimize · 10h ago
- Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia Psychiatric Times · 10h ago
- MapLight shares sink on mixed ph. 2 schizophrenia readout Fierce Biotech · 10h ago
Topics
Related trends
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline with a $2.2 billion acquisition of autoimmune biotech firm Forte Biosciences.
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares are sliding despite a second-quarter earnings beat and raised guidance, driven by a "surprisingly soft" business unit.
Imaging study reveals widespread brain connection loss in schizophrenia
Recent imaging studies have uncovered significant brain connectivity loss in individuals with schizophrenia.
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity stock fell by double digits despite securing its first FDA approval for a new breast cancer treatment.